How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,009 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Correlation between physical markers and psychiatric health in a Portuguese systemic lupus erythematosus cohort: The role of suffering in chronic autoimmune disease. (PubMed)

Correlation between physical markers and psychiatric health in a Portuguese systemic lupus erythematosus cohort: The role of suffering in chronic autoimmune disease. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects a large number of people throughout the world. Anxiety, depression and fatigue are common symptoms of SLE that substantially contribute to decreased quality of life. This study investigates the interplay between physical and psychiatric manifestations (...) of lupus. To this end, an SLE patient cohort was examined for correlations between clinical presentation, laboratory tests, and psychological indicators.Seventy-two lupus patients were evaluated for psychological status using a battery of instruments, including assessments for fatigue (CFS & FSS), depression (HADS), anxiety (HADS), overall health (SF-36 & PSQI) and intimate relationship satisfaction (RAS & CSI). Scores from these assessments were correlated with lupus clinical profiles and laboratory

Full Text available with Trip Pro

2018 PLoS ONE

122. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. (PubMed)

Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PR1) and receptor 5 (S1PR5), which has shown therapeutic benefit in clinical trials of relapsing multiple sclerosis and ulcerative colitis. Ozanimod and its active metabolite, RP-101075, exhibit a similar specificity profile (...) at the S1P receptor family in vitro and pharmacodynamic profile in vivo. The NZBWF1 mouse model was used in therapeutic dosing mode to assess the potential benefit of ozanimod and RP-101075 in an established animal model of systemic lupus erythematosus. Compared with vehicle-treated animals, ozanimod and RP-101075 reduced proteinuria over the duration of the study and serum blood urea nitrogen at termination. Additionally, ozanimod and RP-101075 reduced kidney disease in a dose-dependent manner

Full Text available with Trip Pro

2018 PLoS ONE

123. HLA Class III: A susceptibility region to systemic lupus erythematosus in Tunisian population. (PubMed)

HLA Class III: A susceptibility region to systemic lupus erythematosus in Tunisian population. Short tandem repeats (STR) are usually used as informative polymorphic markers for genetic mapping and for disease susceptibility analysis. The involvement of these microsatellite markers localized in the MHC region was reported in many auto-immune diseases. In this study we analyzed for the first time eight polymorphisms of microsatellite loci at the HLA region: D6S291, D6S273, TNFa, b and c, MICA (...) , D6S265 and D6S276, in Tunisian systemic lupus erythematosus (SLE) patients.We performed a case control study in which the microsatellite loci were amplified using specific primers labeled with NED, VIC, PET or 6-FAM and analyzed using GeneScan software 3.7. For the statistical analysis, we used SPSS software and we performed a sub-haplotype scoring test using the haplo.stats software developed in the R language.We found that two mean associated regions existed; the most statistically significant

Full Text available with Trip Pro

2018 PLoS ONE

124. Immune responses to an early lytic cytomegalovirus antigen in systemic lupus erythematosus patients: T-cell responses, cytokine secretions and antibody status. (PubMed)

Immune responses to an early lytic cytomegalovirus antigen in systemic lupus erythematosus patients: T-cell responses, cytokine secretions and antibody status. We investigated immune responses to a lytic cytomegalovirus antigen (CMVpp52), and to a lytic human herpes virus (HHV) 6 antigen (HHV6p41), in systemic lupus erythematosus (SLE) patients and healthy controls (HCs), in order to clarify if the previously established impaired responses to Epstein-Barr virus (EBV) in SLE patients

Full Text available with Trip Pro

2018 PLoS ONE

125. Mortality and Functionality after Stroke in Patients with Systemic Lupus Erythematosus

Mortality and Functionality after Stroke in Patients with Systemic Lupus Erythematosus To investigate mortality and functional impairment after stroke in systemic lupus erythematosus (SLE).Using Swedish nationwide registers, we identified 423 individuals with SLE and 1652 people without SLE who developed a first-ever ischemic or hemorrhagic stroke (1998-2013) and followed them until all-cause death or for 1 year. HR for death after ischemic or hemorrhagic stroke and the risk ratio of functional

2017 EvidenceUpdates

126. Performance of Screening Tests for Cognitive Impairment in Systemic Lupus Erythematosus

Performance of Screening Tests for Cognitive Impairment in Systemic Lupus Erythematosus There is a need for a cognitive function screening test that can be administered to patients with systemic lupus erythematosus (SLE) in clinic. The objectives of this study were to determine (1) prevalence of cognitive impairment (CI) in SLE by the Montreal Cognitive Assessment (MoCA), Mini Mental State Examination (MMSE), in relation to the Hopkins Verbal Learning Test-Revised (HVLT-R), and Perceived

2017 EvidenceUpdates

127. 46-Year Trends in Systemic Lupus Erythematosus Mortality in the United States, 1968 to 2013: A Nationwide Population-Based Study. (PubMed)

46-Year Trends in Systemic Lupus Erythematosus Mortality in the United States, 1968 to 2013: A Nationwide Population-Based Study. No large population-based studies have been done on systemic lupus erythematosus (SLE) mortality trends in the United States.To identify secular trends and population characteristics associated with SLE mortality.Population-based study using a national mortality database and census data.United States.All U.S. residents, 1968 through 2013.Joinpoint trend analysis

Full Text available with Trip Pro

2017 Annals of Internal Medicine

128. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial

Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial To compare the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS) versus azathioprine (AZA) in patients with active systemic lupus erythematosus (SLE) disease.A multicentre, 24-month, superiority, open-label, randomised controlled trial (NCT01112215) was conducted with 240 patients (120 per arm) receiving either EC-MPS (target dose: 1440 mg (...) /day) or AZA (target dose: 2 mg/kg/day) in addition to prednisone and/or antimalarials. The primary endpoint was the proportion of patients achieving clinical remission, assessed by SLE Disease Activity Index 2000 (SLEDAI-2K) and British Isles Lupus Assessment Group (BILAG), at 3 and 24 months. Secondary endpoints included time to clinical remission, BILAG A and B flare rates, time to flare, corticosteroid reduction and adverse events (AEs).Proportion of patients achieving clinical remission

2017 EvidenceUpdates

129. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study

Stroke in systemic lupus erythematosus: a Swedish population-based cohort study To study the occurrence of ischaemic and haemorrhagic stroke in systemic lupus erythematosus (SLE) compared with the general population by age, sex and time since SLE diagnosis METHODS: Adults with incident SLE were identified from the Swedish National Patient Register (NPR, n=3390) and general population comparators from the Total Population Register were matched on age, sex and county (n=16730). Individuals were

Full Text available with Trip Pro

2017 EvidenceUpdates

130. Gene-function studies in systemic lupus erythematosus. (PubMed)

Gene-function studies in systemic lupus erythematosus. The aim of this review is to discuss recent developments in our understanding of how systemic lupus erythematosus (SLE)-associated genes contribute to autoimmunity.Gene-function studies have revealed mechanisms through which SLE-associated alleles of IFIH1, TNFAIP3, IRF5, and PRDM1 likely contribute to the development of autoimmunity. Novel research has identified Mac-1 (encoded by ITGAM), CaMK4, and iRhom2 as plausible therapeutic targets (...) in lupus nephritis.The work discussed in this review has broad implications for our understanding of the pathogenesis of SLE and for the development of novel therapeutic strategies.

2019 Current Opinion in Rheumatology

131. The study of interactions between genome and exposome in the development of systemic lupus erythematosus. (PubMed)

The study of interactions between genome and exposome in the development of systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease characterized by a broad spectrum of clinical and serological manifestations. This may reflect a complex and multifactorial etiology involving several identified genetic and environmental factors, though not explaining the full risk of SLE. Established SLE risk genotypes are either very rare or with modest

Full Text available with Trip Pro

2019 Autoimmunity reviews

132. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. (PubMed)

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. Plasmacytoid DCs (pDC) produce large amounts of type I IFN (IFN-I), cytokines convincingly linked to systemic lupus erythematosus (SLE) pathogenesis. BIIB059 is a humanized mAb that binds blood DC antigen 2 (BDCA2), a pDC-specific receptor that inhibits the production of IFN-I and other inflammatory mediators when ligated. A first-in-human study was conducted to assess safety, tolerability (...) blood and skin biopsies were measured. Skin disease activity was determined using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A).Single doses of BIIB059 were associated with favorable safety and PK profiles. BIIB059 administration led to BDCA2 internalization on pDCs, which correlated with circulating BIIB059 levels. BIIB059 administration in patients with SLE decreased expression of IFN response genes in blood, normalized MxA expression, reduced immune

Full Text available with Trip Pro

2019 The Journal of clinical investigation

133. Seborrheic area involvement in patients with systemic lupus erythematosus. (PubMed)

Seborrheic area involvement in patients with systemic lupus erythematosus. The most characteristic skin manifestation of systemic lupus erythematosus (LE) is malar rash characterized by an erythematous congestive sometimes secondarily squamous eruption over the cheeks and nasal bridge, that typically spares nasolabial folds. This rash is referred to as "acute cutaneous lupus erythematosus" (ACLE) (1). Recently, 2 SLE patients with remarkable skin involvement of seborrheic area (SA) came to our

2019 Journal of the European Academy of Dermatology and Venereology

134. Biomarkers of erosive arthritis in systemic lupus erythematosus: Application of machine learning models. (PubMed)

Biomarkers of erosive arthritis in systemic lupus erythematosus: Application of machine learning models. Limited evidences are available on biomarkers to recognize Systemic Lupus erythematosus (SLE) patients at risk to develop erosive arthritis. Anti-citrullinated peptide antibodies (ACPA) have been widely investigated and identified in up to 50% of X-ray detected erosive arthritis; conversely, few studies evaluated anti-carbamylated proteins antibodies (anti-CarP). Here, we considered

Full Text available with Trip Pro

2018 PLoS ONE

135. Cognitive dysfunction improves in systemic lupus erythematosus: Results of a 10 years prospective study. (PubMed)

Cognitive dysfunction improves in systemic lupus erythematosus: Results of a 10 years prospective study. Cognitive impairment (CI) has been described in 3-80% of Systemic lupus erythematosus (SLE) patients but only short-term studies evaluated its over-time changes, suggesting that CI is usually a stable finding. We aimed at evaluating the changes of SLE-related CI in a 10-years prospective single center cohort study.We evaluated 43 patients (M/F 5/38; mean age = 45.7±10.1 years; mean disease (...) % for both degrees). After 10 years, CI improved in 50% of patients, while 10% worsened. Impaired memory (P = 0.02), executive functions (P = 0.02) and abstract reasoning (P = 0.03) were associated with dyslipidemia at T0. Worsening of visuospatial functions was significantly associated with dyslipidemia and Lupus Anticoagulant (P = 0.04 for both parameters). Finally, GCD significantly correlated with chronic damage measured by SLICC/damage index at T0 (r = 0.3; P = 0.04) and T1 (r = 0.3; P = 0.03

Full Text available with Trip Pro

2018 PLoS ONE

136. Understanding Non-Adherence with Hydroxychloroquine Therapy in Systemic Lupus Erythematosus. (PubMed)

Understanding Non-Adherence with Hydroxychloroquine Therapy in Systemic Lupus Erythematosus. Hydroxychloroquine (HCQ) is a cornerstone to managing systemic lupus erythematosus (SLE), yet adherence to medication is poor. We sought to measure the association of adherence with five 'dimensions of adherence' as articulated by the World Health Organization for chronic conditions: the patient's socioeconomic status, and patient-, condition-, therapy-, and healthcare-system-related factors. Our long

2019 Journal of Rheumatology

137. Atherosclerotic Vascular Events in Systemic Lupus Erythematosus - an Evolving Story. (PubMed)

Atherosclerotic Vascular Events in Systemic Lupus Erythematosus - an Evolving Story. Atherosclerotic vascular events (AVEs) are a major cause of mortality and morbidity in systemic lupus erythematosus (SLE). We aimed to determine the impact of early recognition and therapy for both classic risk factors for AVE and for SLE on the burden of AVEs in lupus in recent decades.Inception patients who entered the University of Toronto lupus Clinic between 1975 and 1987 followed to 1992 (Cohort 1 (...) ) and between 1999 and 2011 followed to 2016 (Cohort 2) were studied. AVEs, attributed to atherosclerosis, and occurring during the 17 years were identified. Lupus disease activity and therapy as well as hypertension, hypercholesterolemia, hyperglycemia and smoking were assessed. Analysis included descriptive statistics on baseline characteristics, traditional risk factors over the follow up, outcome rates by each 100 person years; Kaplan-Meier cumulative AVE curves, as well as competing risk Cox models

2019 Journal of Rheumatology

138. Fatigue Measurements in Systemic Lupus Erythematosus. (PubMed)

Fatigue Measurements in Systemic Lupus Erythematosus. Fatigue is a frequent, disabling issue in SLE. It is, however, difficult to quantify. The Ad Hoc Committee on SLE Response Criteria for Fatigue in 2007 recommended using the Krupp Fatigue Severity Scale (FSS). Since then, the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue scale has also been validated in SLE. We performed a review of instruments used to measure fatigue in adult SLE patients from 2007 onward.We searched

2019 Journal of Rheumatology

139. Predicting flares in patients with stable systemic lupus erythematosus. (PubMed)

Predicting flares in patients with stable systemic lupus erythematosus. Data on flares in Asian patients with systemic lupus erythematosus (SLE) are scarce. Here, we aim to identify the baseline predictors of flares in a cohort of Southeast Asian patients with SLE.Consecutive adult patients with prevalent SLE according to the 1997 ACR or 2012 SLICC criteria were enrolled and followed three-monthly. Clinical and laboratory data were collected at every visit using a standardised protocol. Flares

2019 Seminars in arthritis and rheumatism

140. Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus. (PubMed)

Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is characterized by abnormalities in B cell and T cell function, but the role of disturbances in the activation status of macrophages (Mϕ) has not been well described in human patients. To address this, gene expression profiles from isolated lymphoid and myeloid populations were analyzed to identify differentially expressed (DE) genes

Full Text available with Trip Pro

2018 PLoS ONE

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>